← All trials
NCT06978062
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 20, 2026
- Primary completion
- Sep 11, 2028
- Completion date
- Sep 28, 2029
- First posted
- May 18, 2025
- Last posted
- Jun 5, 2025
- Enrollment
- 27
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- University of MannheimOfficial
- Johannes Gutenburg UniversityOfficial
- University of OxfordOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.